Timely genetic diagnosis not only improves understanding of the pathogenesis but, more importantly enables the initiation of targeted therapies—such as abatacept in CTLA-4 deficiency—with a significant positive impact on patients’ quality of life. Here, CTLA4 is linked to hyperinsulinemic hypoglycemia, familial, 4.